UK markets closed

Inhibikase Therapeutics, Inc. (IKT)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.5741-0.0459 (-7.40%)
At close: 03:57PM EST
0.5720 -0.00 (-0.37%)
After hours: 06:53PM EST
Currency in USD

Valuation measures4

Market cap (intra-day) 14.48M
Enterprise value -11.68M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)0.59
Enterprise value/revenue N/A
Enterprise value/EBITDA 0.62

Trading information

Stock price history

Beta (5Y monthly) N/A
52-week change 3-62.97%
S&P500 52-week change 3-11.32%
52-week high 31.8000
52-week low 30.4400
50-day moving average 30.7432
200-day moving average 30.9341

Share statistics

Avg vol (3-month) 3103.22k
Avg vol (10-day) 333.97k
Shares outstanding 525.23M
Implied shares outstanding 6N/A
Float 818.28M
% held by insiders 121.32%
% held by institutions 118.34%
Shares short (14 Nov 2022) 4196.83k
Short ratio (14 Nov 2022) 41.07
Short % of float (14 Nov 2022) 40.99%
Short % of shares outstanding (14 Nov 2022) 40.78%
Shares short (prior month 13 Oct 2022) 4191.64k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)29 Sept 2022

Profitability

Profit margin 0.00%
Operating margin (ttm)-30,468.63%

Management effectiveness

Return on assets (ttm)-31.62%
Return on equity (ttm)-55.10%

Income statement

Revenue (ttm)61.82k
Revenue per share (ttm)0.00
Quarterly revenue growth (yoy)-97.80%
Gross profit (ttm)-8.26M
EBITDA N/A
Net income avi to common (ttm)-18.82M
Diluted EPS (ttm)-0.7630
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)26.53M
Total cash per share (mrq)1.05
Total debt (mrq)374.07k
Total debt/equity (mrq)1.49
Current ratio (mrq)8.71
Book value per share (mrq)1.00

Cash flow statement

Operating cash flow (ttm)-17.89M
Levered free cash flow (ttm)-11.21M